Table 2

Physicians’ experience of IDegLira use

Total (n=235)Primary care (n=132)Secondary care (n=103)
Percentage of physicians who responded that their average IDegLira patient achieved their target HbA1c767774
Target HbA1c level, %7.17.27.0
Average time taken and resources required between IDegLira initiation and achievement of HbA1c targets
 Average number of visits required3.43.73.0
 Average number of telephone calls required2.32.22.5
 Average number of months5.85.95.7
Average dose of IDegLira when the average patient was in glycemic control, dose steps282433
Number of respondents prescribing a maximum dose of 50 dose steps to an average IDegLira patient in glycemic control15411
Percentage of physicians who responded that their average patient discontinued IDegLira151713
Average percentage of respondents’ total IDegLira-treated patient population who discontinued IDegLira (range)15 (1–80)16 (1–80)14 (1–50)
  • HbA1c, glycated hemoglobin; IDegLira, insulin degludec/liraglutide.